| 研究概要 |
Results of the research above revealed that AR expression in TNBC specimens correlated with lower levels of proliferation and this association was stronger in samples that also expressed enzymes for androgen synthetic pathways. This result was actually contrary to our original hypothesis, based on the research reports from others that groups characterized by very high levels of androgen receptor in the absence of estrogen receptor had a worse prognosis, and is contrary to the results of the dominate group in this area of research. The novelty of this finding was recognized by the research being awarded a prize in the presidential poster competition at the international scientific meeting ENDO2012, lead to an invitation to speak at the 15^<th> International congress on hormonal steroid and hormones & cancer in Kanazawa in 2012 and was subsequently published in the journal cancer science. Since this original contradictory finding we have been searching through possible explanations that reconcile an overall trend showing the pathological analysis reveals the androgen receptor to be a potential suppressor of proliferation, yet cell line and molecular analysis suggesting the androgen receptor as a potential oncogene. Recent data, currently under consideration for publication in the journal breast cancer research and treatment suggests that in triple negative breast cancer there may be at least two distinct types of AR expressing TNBC. In tandem with two recent reports from other groups this may provide important information in patient selection when choosing AR targeting agents as a therapy in TNBC. In addition to this, recent papers suggesting a role of ERβ in breast cancer, combined with the known overlap between androgen receptor and ERβ receptor ligands has led to an expansion of the project to investigate these factors in TNBC.
|
